Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
ELV vs UNH: Elevance Health and UnitedHealth Group Chart Different Courses After Q3 Results

ELV vs UNH: Elevance Health and UnitedHealth Group Chart Different Courses After Q3 Results

Key Takeaways

  • ELV (Elevance Health) delivered a stronger-than-expected third quarter, lifted its 2026 adjusted earnings guidance, and pointed to at least 12% EPS growth for 2027.
  • UNH (UnitedHealth Group) is further along in its margin-recovery effort, posting a notably better medical care ratio and marking its third guidance raise of the year.
  • The two companies present distinct profiles: Elevance draws on a diversified insurance book plus its Carelon services platform, while UnitedHealth combines its insurance operations with the broader Optum healthcare-services ecosystem.
  • Recent performance has diverged, with UnitedHealth mounting a sharper rebound from its lows while Elevance has maintained steadier, more diversified earnings momentum.
  • Both face common sector challenges, including higher medical costs, Medicaid redetermination effects, and regulatory scrutiny around Medicare Advantage and pharmacy benefit managers.
  • For additional details on each name, review ELV Major News and ELV Today's Price Move, or UNH Major News and UNH Today's Price Move.
  • For automated, data-driven insights on these and thousands of other tickers, explore Trending AI Robots.

Introduction

Elevance Health and UnitedHealth Group rank among the largest publicly traded managed-care organizations in the United States, so this comparison matters for investors tracking the health-insurance sector. Both have worked through a challenging stretch marked by elevated medical utilization, policy changes, and regulatory pressure, yet their trajectories have begun to differ in meaningful ways. Long-term investors looking for steady compounders and traders monitoring relative performance can both gain from understanding how these bellwethers vary in business mix, growth drivers, and market positioning. The analysis that follows looks at recent results and observable trends to clarify how ELV and UNH compare at present. I also checked this using Tickeron’s AI Screener to see how the stocks line up against peers.

ELV Overview and Recent Performance

Elevance Health, which rebranded from Anthem in 2022, runs a diversified health-benefits operation across commercial, Medicaid, Medicare, and individual plans, together with its Carelon services business that includes pharmacy benefit management, behavioral health, and care delivery. In recent weeks, the company reported third-quarter results that exceeded consensus, with adjusted EPS of $6.99 versus roughly $4.70 expected and operating revenue near $50.4 billion. Management raised its full-year 2026 adjusted EPS guidance to at least $29.00 and improved its operating cash-flow outlook.

The quarter featured a 70-basis-point improvement in the benefit expense ratio to 90.6%, supported by stronger Medicare Advantage and individual-market results. Medical membership fell by about 487,000 year over year to roughly 44.9 million, reflecting a deliberate shift in positioning. Carelon helped diversify outcomes, with operating revenue rising 5% and operating gain advancing 17%. Analyst price-target increases have helped sentiment, although part of the earnings beat came from non-operating items, which tempered the market reaction.

UNH Overview and Recent Performance

UnitedHealth Group is the largest U.S. health insurer and a diversified healthcare enterprise that pairs its UnitedHealthcare insurance segment with the Optum platform covering Optum Health, Optum Rx, and Optum Insight. In recent weeks, the company reported third-quarter adjusted EPS of $4.69, well above the roughly $4.12–$4.14 consensus, on revenue of about $112.7 billion. It raised full-year 2026 adjusted EPS guidance to at least $20.50, marking the third increase this year.

The clearest development was margin recovery: the medical care ratio improved to 88.4% from 89.9% a year earlier, aided in part by favorable prior-period reserve development. Membership declined to about 48.3 million from 50.1 million as the firm intentionally exited unprofitable markets and plans. Optum Health showed a sharp swing, with operating earnings rising to roughly $735 million from $41 million a year earlier. Under returning CEO Stephen Hemsley, the company has emphasized profitability over enrollment growth, a move that has improved sentiment and supported a substantial rebound from 2025 lows.

Head-to-Head Comparison

The companies differ most clearly in scale and structure. UnitedHealth is roughly four times Elevance’s market capitalization and operates a larger, more integrated services engine through Optum. Elevance, by contrast, maintains a more balanced mix across commercial and government lines and leans heavily on Carelon for diversification. In growth drivers, Elevance is focused on margin expansion and Carelon cross-selling, while UnitedHealth is consolidating after a deliberate pullback from lower-margin business.

On recent momentum, UnitedHealth has posted the more dramatic recovery, rising substantially from its early-2026 trough as margin repair took hold. Elevance has been comparatively steadier, with gains linked to consistent earnings execution rather than a rebound narrative. Risk factors also vary in emphasis: Elevance carries notable Medicaid and state-rate sensitivity, whereas UnitedHealth faces the largest Medicare Advantage footprint and ongoing regulatory scrutiny. Valuation and dividend profiles differ as well, with UnitedHealth offering a higher yield and Elevance a lower payout ratio, reflecting distinct capital-return approaches. From what I see, these distinctions matter when weighing relative risk and reward.

Tickeron AI Verdict

Based on observable trend consistency, stability, and relative positioning, Tickeron’s AI would likely favor UnitedHealth Group at present, given its stronger established uptrend, improving margin trajectory, and clearer earnings-recovery catalysts across its insurance and Optum segments. Elevance Health remains a solid, well-diversified candidate with attractive long-term fundamentals, but its momentum has been less decisive and its recent beat partly reflected non-operating items. This assessment is probabilistic rather than definitive: both names carry exposure to medical-cost trends and policy risk, and relative positioning could shift as new data emerges. Traders and investors should weigh trend strength against valuation and their own objectives. I’m watching this closely for any signs of convergence or further divergence.

Exploring AI-Driven Trading Strategies

I’ve found that reviewing Tickeron’s Trending AI Robots page provides a useful snapshot of top-performing automated strategies across thousands of tickers. The platform hosts hundreds of AI trading bots, each with its own style, timeframe, performance record, and set of covered securities. Because market conditions shift, only the bots best suited to the current environment appear in the curated rankings. Checking these regularly helps identify approaches aligned with prevailing momentum and volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UNH, ELV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


UNH's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of hospital and medical service plans

Industry ManagedHealthCare

Industry
Managed Health Care
Address
1 Health Drive
Phone
+1 800 328-5979
Employees
390000
Web
https://www.unitedhealthgroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.